These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 14524195)
1. Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab). National Advisory Committee on Immunization Can Commun Dis Rep; 2003 Sep; 29():1-15. PubMed ID: 14524195 [No Abstract] [Full Text] [Related]
2. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease. Cabalka AK Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269 [TBL] [Abstract][Full Text] [Related]
3. Use of respiratory syncytial virus surveillance data to optimize the timing of immunoprophylaxis. Panozzo CA; Stockman LJ; Curns AT; Anderson LJ Pediatrics; 2010 Jul; 126(1):e116-23. PubMed ID: 20547651 [TBL] [Abstract][Full Text] [Related]
4. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042 [TBL] [Abstract][Full Text] [Related]
5. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Paes B; Steele S; Janes M; Pinelli J Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698 [TBL] [Abstract][Full Text] [Related]
6. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease. Saji T; Nakazawa M; Harada K Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515 [TBL] [Abstract][Full Text] [Related]
7. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease? Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363 [TBL] [Abstract][Full Text] [Related]
10. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627 [TBL] [Abstract][Full Text] [Related]
11. Passive immunisation of preterm infants with palivizumab against RSV infection. Harkensee C; Brodlie M; Embleton ND; Mckean M J Infect; 2006 Jan; 52(1):2-8. PubMed ID: 16236360 [TBL] [Abstract][Full Text] [Related]
12. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry. Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J; Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822 [TBL] [Abstract][Full Text] [Related]
13. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. DeVincenzo JP; Hall CB; Kimberlin DW; Sánchez PJ; Rodriguez WJ; Jantausch BA; Corey L; Kahn JS; Englund JA; Suzich JA; Palmer-Hill FJ; Branco L; Johnson S; Patel NK; Piazza FM J Infect Dis; 2004 Sep; 190(5):975-8. PubMed ID: 15295704 [TBL] [Abstract][Full Text] [Related]
14. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Gill MA; Welliver RC Expert Opin Biol Ther; 2009 Oct; 9(10):1335-45. PubMed ID: 19764889 [TBL] [Abstract][Full Text] [Related]
15. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients. Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443 [TBL] [Abstract][Full Text] [Related]